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Abstract
Bone Mineral Density (BMD) tells us about the amount of minerals in bones,
and gives an indication of bones strength. The BMD is influenced by genetic
factors as well as nutrition, sex hormone status, glucocorticoid therapy and
physical activity among others. In this project we have focused on genes making
an impact on BMD, by using mathematics and regression. Since the number
of explanatory variables x (genes) overrides the number of response variables y
(women) we use the variable selection method called LASSO. In that way we are
able to sort out the genes with the highest contribution to BMD. We discovered
55 unique genes, among which ATP5SL, TNXA /// TNXB, SOST, PBXIP1,
SNCA, GTF2F2, DPP8, C4orf31, TFDP2 and MCF2L were among those with
the strongest association to BMD. SOST, AFFX-M27830 M at, PBXIP1 and
RNF216 found by LASSO, confirms previous literature. Most of the genes
seems to be highly associated with and probably have some impact on BMD.
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1 BMD - Bone Mineral Density
Bone Mineral Density (BMD) tells us about the amount of minerals in bones,
and gives an indication of bones strength. Geometry, micro-architecture, min-
erals and extracellular matrix composition makes up a bone’s construction and
strength. There is an association between high and low BMD and strong and
fragile bone, respectively [16]. A reduction of BMD and deterioration of the mi-
cro architecture of bone tissue, is a sign of either ostopenia or osteoporosis (OP),
and increase the risk of bone fractures [16]. In general practice, BMD is usually
measured by dual-energy X-ray absorptiometry (DEXA). The World Health Or-
ganization (WHO) defines osteoporosis as a BMD ≤ −2, 5 standard deviations
below the mean value for a young healthy adult. Values between −2, 5 and −1
are defined as Osteopenia. [11]. There is a clear inheritability of characteristics
of bone mineral density, and examples of genes found earlier to have an impact
on bone, are bone morphogenetic protein 2 (BMP2 ), low-density lioprprpotein
receptor related protein 5 (LRP5 ) and osteoprotegrin (TNFRSF11B). Other
factors known to influence BMD, are nutrition (e.g. Calcium insufficiency), sex
hormone status (especially oestrogen deficiency), glucocorticoid therapy and
physical activity [17]. It is the most prevalent metabolic bone disorder world-
wide. One in three women and one in five men over the age of 50 are affected
[12].
In the U.S. and Scandinavia, rates are about 25% higher for getting a frac-
ture due to OP compared to other European countries. In the U.S. 40% of all
Caucasian women and 13% of all Caucasians of similar age will suffer a fracture
of clinical significance due to OP during their lives. These fractures have con-
sequences on both population healthcare and economical/societal aspects, and
is of big importance due to an increasingly ageing population [16].
2 Genomics
Genes hold the information of what kind of product a cell shall produce. Most
often this is proteins, but it can also be different kinds of RNA such as ribo-
somal RNA (rRNA), which functions as a component in ribosomes (complexes
responsible for protein synthesis) and Transfer RNA (tRNA) [2] carries its spe-
cific amino acid to the ribosomes for protein synthesis. Small nuclear RNA
(snRNA) plays a role in modulation of messenger RNA(mRNA) [2] which is
the template for the proteins that is to be produced. What kind and amount
of product that are produced, depend on the regulation of the gene expression
of the cell, and is regulated in many different ways at both the transcriptional
level, where RNA is transcribed and modulated from DNA, and at the trans-
lational level, where the modulated mRNA are translated to proteins [2]. The
genetic code stored in a cell’s DNA gives the base for the gene expression. In the
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code, we find promoters, which are the place on the DNA where the transcrip-
tion starts. Together with hormones, vitamins and proteins called transcription
factors, the first part of the gene expression process is initiated here with an
enzyme called RNA polymerase [2]. The genes serve as a code dictating how
the sequence of a RNA-strand should be put together. In eukaryotic organisms,
it is first transcribed a pre −mRNA, that is further modificated to become a
mature mRNA. One of the modulation processes is called splicing. Here, inter-
fering segments called introns are removed, and the remaining segments called
exons are put together in new ways. This gives rise to many different pheno-
types from one single gene. After undergoing some more changes, the mRNA
is further translated to proteins, and regulation may also occur at this level
[2]. In addition to regulation at the transcriptional and translational level, the
DNA may undergo epigenetic changes, which means that the gene expression is
changed without interference of the DNA sequence. This is done by changes to
the access to the DNA. The amount of copies of a gene may also make an in-
fluence, as well as other processes we will not mention further here. It is widely
known that genes are inheritable, and traits seen in an organism are, among
other, controlled by the gene expression-process. Interesting for the present
work is for example that mothers with lower bone mass, more frequently have
children with significantly lower bone mass than the general female population
[4].
3 How to analyze gene expression
In order to find out which genes that show the greatest impact on a disease, we
need to compare the gene expression in individuals with the disease and without
the disease. This is done by detecting and measuring the final gene products,
RNA and proteins. There are several techniques to do this and some of the
most common are presented here:
Northern blotting gives a measurement of the amount and size of particu-
lar mRNA molecules. Through electrophoresis are mRNA molecules separated
and then transferred to a membrane where they are hybridized to a radioactive
probe of the sequence wanted to be analysed. Band-analysis of the membrane
with the radioactive probes are done by autoradiography, and gives a measure
of the amount and size of the chosen mRNA[2].
PCR - Polymerase Chain Reaction is another approach for measuring mRNA.
A single-stranded DNA or RNA are made from a targeted gene sequence from
the cell tested through reverse transcription. The product, cRNA/cDNA is then
amplified through several cycles of replication. The fluorescence from labelled
hybridization probes or intercalating dyes are measured. From this you can
get an absolute measurement of the number of copies of original mRNA. This
method is very sensitive, and theoretically is it possible to detect a single mRNA
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molecule as long as we know the sequence that is needed for initiation of the
process[14].
To analyse many genes within a sample simultaneously, hybridization mi-
croarray is used. This is the method that has been used in this project. A
microarray is a chip containing probes to every known gene in the genome of
an organism. The principle is to convert mRNA to cDNA labelled with a fluo-
rescent tag. The cDNA is then exposed to the chip. By measuring the amount
of fluorescence at each spot, we are able to measure the amount of that partic-
ular mRNA and thereby discover if there are any differences in gene expression
between a diseased and healthy individual or between two different cells from
different locations on the body[2].
Other methods, such as Serial analysis of gene expression (SAGE) and RNA-
Seq, can provide relative measure of the cellular concentration of different mR-
NAs. RNA-Seq can also be used to identify single-nucleotide polymorphisms
(SNPs), splice variants and novel genes in addition to profile expression in or-
ganisms where little or no sequence information are available[18].
Some of the methods used to analyze proteins, are among other Enzyme-
linked immunosorbent assays (ELISA). Here antigen, the protein, is bound to
a microtiter dish due to an antibody specific for that antigen at the bottom
of the dish. The probes that are used, are antibodies specific for the different
proteins and they are covalently bound to an enzyme that will change colour of
its substrate when exposed to it. The amount of colour from the transformed
substrate can tell us about the amount of protein.
Another way is to use Western Blot, which is quite similar to Northern blotting.
Instead of RNA-molecules, protein molecules are separated by electrophoresis
and transferred (blotted) to a membrane. A antibody labeled probe is also used
here, and it produces a band at the location of its antigen on the membrane
that is further analyzed [2].
4 Bones and BMD
4.1 Materials
Mature bone consists of a mixture of about 70% inorganic salts and 30% or-
ganic matrix. Of the organic matrix, 90% is collagen and the rest being ground
substance proteoglycans and a group of non-collagen molecules involved in the
regulation of bone mineralisation. The ground substance proteoglycans’ task
is among other controlling the water content of bones and probably regulating
formation of collagen fibers in order to get an appropriate subsequent matrix
mineralisation. Other non-collagen organic material is osteocalcin, responsi-
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Figure 1: Howship lacunae with osteoclast[9].
ble for binding Calcium during the mineralisation process, osteonectin, which
probably serves some bridging function between collagen and the mineral com-
ponent, sialoproteins, a surface glycoprotein and certain other proteins [19]. The
inorganic component consist of calcium and phosphate crystallized as hydroxya-
patite, and is conjugated with small portions of magnesium carbonate, sodium
and potassium [19].
4.2 Osteoblasts and osteoclasts
Anabolic cells called osteoblasts, have the responsibility of synthesis and secre-
tion of collagen and other organic matrix which results in the production of os-
teoid. They also have the responsibility of deposition of calcium salts in the bone
matrix [19]. As the osteoblasts produce organic matrix, they get surrounded by
this matrix and eventually get trapped and transformed to osteocytes. The Os-
teocytes’ main responsibility is to take part in the mineral homeostasis of the
bone matrix. The cell body of the osteocyte makes a space called lacuna, and
the cells dendrites make channels in the matrix called canaliculi. Through these
canaliculies, the cell gets its nutritients. In the bone there are also katabolic
cells called osteoclasts. They resorb bone through the enzyme acid phosphatase
and leave behind cavities called Howship lacunas, see Figure 1. One osteclast
can resorb as much bone matrix as 150 osteoblasts can produce per unit of time
[6].
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Figure 2: Howersian canal with surrounding matrix [3].
4.3 Anatomy
In the microscopic bone matrix, there are small units called Osteons or Haver-
sian systems, see Figure 2. These units are made up of concentric shells or bone
lamellae, Haversian lamellae, and they form a channel called Haver’s channel.
This channel contains capillares and nerves. The Haversian systems are made
by osteoblasts which produce layers of lamellae from the center of the osteon,
and eventually ends up being trapped between the lamellaes as osteocytes. In
young individuals, the osteons lays paralell, and as we get older the lamellae will
overlap each other. Macroscopically, the bones are made up of to types of bones,
compact bone and cancellous bone. The compact bone makes up all parts of the
skeletal surface. The cancellous bone is found mainly in the end of the bones
and in the short bones. It consist of a network of supporting beams, trabeculae,
which direction are decided by the bones tension and compression lines, trajec-
tories. This give the bones the property of having maximum strength with a
minimum of material [6]. In osteoporosis a widening of the haversian canals is
seen microscopically as well as a macroscopically thinning and widely separa-
tion of the trabeculae. It happens due to increased resorbtion by osteoclasts,
reduced bone formation by osteoblasts and reduced maintenance of osteocytes
[17].
5 Bone and genomics
In order to make some impact on treatment or prevention of OP, several stud-
ies have been done regarding the genetic significance for BMD. In an icelandic
study on first degree relatives in several families, it has been discovered that few
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genes influence low bone mass considerably, in addition to several other genes
with a small effect [16].
Some twin studies have showed that bone mass is about 80% genetically de-
termined. Single-nucleotide polymorphisms (SNPs) have also been identified to
make an impact on BMD, but through wide genomic scan studies, it is esti-
mated that these account for only about 4% of the total variation in hip and
spine BMD [11]. Other smaller studies have tried to describe gene expression
related to BMD and OP in bone biopsies. One of them is the Hopwood study,
which consisted of 10 bone autopsy samples (controls), 10 biopsies from patients
with osteoarthritis (OA, second control) and 10 with OP. The study showed 150
differentially expressed genes in OP-bone compared to OA and control-biopsies
[16].
In this project, we will try to identify which genes are associated with BMD
variation through regression, using the variable selection-method called LASSO.
6 Linear regression
6.1 Univariate linear regression
The simplest type of regression, is linear univariate regression. It is used when
we are studying the relation between an explanatory variable x (for example
the expression of a single gene) and a response variable y (for example BMD).
In many situations, we do not know this relation, but we can assume that it is
linear of the form y = a+bx, where a is the intersection point on the Y-axis and
b is the slope of the line. If you have n number of points (e1, e2, e3, ..., en), each
with the value (x1, y1), (x2, y2), (x3, y3),..., (xn, yn), our main objective is to do
a regression and estimate the values for a and b so that the vertical distance to
the line y = a+ bx is as small as possible for all the points, see Figure 3.
This is normally done by using the least square method, expressed by
min
a,b
n∑
i=1
(yi − a− bxi)2.
As seen in the figure, this formula takes the distance from the line to each
point, squares the distances in order to get positive values and in the end sums
all the distances. The values of a and b are found by deriving the formula, and
putting the derivative equality, in order to find the minimal extremal of the
graph [1].
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Figure 3: Linear regression example
6.2 Regression with several independent variables
6.2.1 Linear multivariate regression with p<n
In medicine, there is seldom only one variable that makes an impact on the
response variable y (we still use BMD as an example for y). Variables such as
height, weight, hormones etc. may have an influence on the BMD. This is ex-
pressed by (x1i, x2i, ..., xpi, yi), where p is the number of influencing variables, y
is the BMD and i is the index of the different samples, ranging from (i = 1, ..., n).
Instead of a line, there is now a function for a plane in a p+1 -dimensional room
with the coordinates y and p numbers of x-coordinates/axes, see Figure 4.
Working with more than one explanatory variable x, the regression formula
will be expressed by:
yi = a+ b1x1i + b2x2i + b3x3i + ...+ bpxpi = a+
p∑
j=1
xjibj for each i
As with linear regression, the values for a and b = (b1, b2, b3, ..., bp) have to be
estimated, in order to find out what impact the variables x1, x2, x3, ..., xp have
on y. As long as p<n the value of a and b1, b2, b3, ..., bp can still be estimated
using the least square method, expressed by
min
a,b
n∑
i=1
(yi − a− b1x1i − b2x2i − b3x3i − ...− bpxpi)2
where y is the response variable and x is a matrix of explanatory variables.
The values of b and their significance with respect to BMD will be one of the
main focuses during this project.
6.2.2 Linear multivariate regression with p>n
In this project, there have been taken biopsies from the spina iliaca of 84 vol-
untary women and at the same time their BMD has been measured. From each
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Figure 4: Linear least squares fitting with p > 1. We seek the linear function of
(x1, x2, ..., xn) that minimizes the sum of squared residuals from Y.
10
biopsy, we get approximately p=25 000 expressions of significance. In the re-
gression function, yi equals BMD and x1i, x2i, x3i, ..., xpi are all the genes for
the i-th woman. bpi is the slope for each of the xip.
We now have more independent variables, x, than samples, which means
p > n, or (#genes > #women). Because of this we are in danger of getting an
infinite number of possible minimal values for a and b.
This is shown by this example, where n = 2 and p = 3:
y1 = b1x11 + b2x12 + b3x13
y2 = b1x21 + b2x22 + b3x23
We put in values to give an example:
3 = 10b1 + 3b2 + 2b3 10 = −b1 + 2b2 + b3
Isolate b1 on a side for the first function: b1 =
3−3b2−2b3
10 .
Isolate b2 on a side for the second function: b2 =
10+b1−b3
2 .
Put the first function in the second function:
b2 =
10+
3−3b2−2b3
10 −b3
2 =
103
23 − 1223b3.
As seen from the answer, the value of b2 depends on the value of b3 since we do
not have a third equation to solve. The same will happen if we put the function
for b2 into the function of b1:
b1 =
3−3( 10+b1−b32 )−2b3
10 =
36−7b3
17 .
Again we get the same problem. The value of b1 will depend on the value
of b3. We miss a last equation for a last sample y3 that would make us able to
solve the whole set. In order to be able to estimate the value of BMD, using
regression, we have somehow to select a certain amount of genes, so that we
get less genes than women, p < n. These genes should be the genes with the
strongest effect on BMD.
7 LASSO
The LASSO-function is defined as:
bˆ = argmin
b
n∑
i=1
(yi − b0 −
g∑
p=1
(bpxip))
2 + λ
g∑
p=1
|bp|.
Here bˆ is the result of the fit. n is the number of women, g is the number of
genes, yi is the value of the BMD for each woman, b0 is where the line crosses
the y-axis (but is not really necessary in this fit) and bp is the coefficient for
each gene xp. The function consist of two parts. The first part of the function,
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is a different way of writing the least square-method that we introduced earlier.
It computes how the linear model
δ∑
p=1
(bpxip) approximates the measured data
yi. We call this term a measure of the fit of the model to the data. The second
part, is a penalty part. Our main goal is to get the fit as small as possible, and
at the same time get the penalty part as small as possible. In order to get the
first part as small as possible, the formula tells us that we should have as many
b’s as possible to get a good approximation. But in this case, this also means
that the penalty value in the second part will be large. If we decide to keep a
variable xip in the linear model, with a certain coefficient bp > 0, then we must
pay a penalty equal to λ|bp|
To decide which b’s that will be kept, we need to determine the values of b
we want to keep and in particular decide which bp = 0 which means we do not
want to keep them. This depends on the value of λ.
If the value of b is small, this probably means that the corresponding gene
has a small impact on the outcome. If we put this b to value zero, the corre-
sponding gene will be taken out of consideration regarding impact on BMD. If
the value of b is high, the corresponding gene most likely makes a big impact
on BMD. This of course will make the least square-part in the LASSO-formula
small, but also make the penalty part large. Both solutions will increase the
penalty, but it seems better with few large b’s than many small b’s. In the
end, the goal is to reduce the number of genes as much as possible, so that the
remaining genes are less than n.
In order to do this, we have to find the right value of λ. If the value of λ is
large, the penalty will be large and many b’s will be forced to zero. We will end
up with few genes. If λ is small, fewer b’s will be put to zero, and we will end
up with more genes [10]. In this project, a method called cross validation will
be used together with LASSO in order to find the right value of λ.
8 Cross Validation
Cross validation is a resampling method and is a much needed tool in modern
statistics. It involves drawing samples from a set of observations, the validation
set and compare these samples with fitted models from the remaining subset of
observations, the training set. The training set uses increasing values of lambda
in order to give us several fitted models. The genes found in the fitted models
from the training sets are used to estimate the response variable, BMD. The
estimated values of BMD is tested against the real values of BMD in the valida-
tion set. The error between the estimated value and the actual value is called
the Mean Squared error, MSE, and we would like to find the value of λ, that
gives us the smallest MSE [10]. We could have chosen to take one of the women
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eksempel.png
Figure 5: The Y-axis gives us the smallest MSE, and the X-axis gives us the
value of lambda that gives us the different MSE. The green dotted line shows
the smallest value of lambda.
as validation set, and the rest of the women as the training set, make a fit from
this, and estimated the MSE1 and repeated this n times with a new woman
as validation set each time. In the end we would have taken the average of all
the MSEn in order to get an estimate of the error [10]. Unfortunately, this
would have taken long time if we have a large n, because the model we use is
slow to fit [10]. To solve this problem, we can use k-fold Cross validation. Here
we divide the observations into k separate groups or folds of about the same
size. One fold will be the Validation set, and the remaining k − 1 folds will be
the training set. The MSE is computed against the first validation set, and is
repeated k-times with a different fold as validation set each time. This results
in k estimates of MSE, MSE1,MSE2,MSE3, ...,MSEk. The final estimate is
computed by averaging these values, see the function [10]
CV(k) =
1
k
k∑
i=1
MSEi
All this is done for a fixed value of λ, and we write CV(λ). In order to choose
which λ is best we take the value of λ for which the CV-error CV(λ) is smallest.
For this purpose we compute CV(λ) for several values of λ in fact regularly over
a grid of λ, see Figure 5.
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9 GLMNET
In order to find the genes, we used the lasso package included in the Matlab
R2013a version. This package is a part of the glmnet package that fits a general-
ized linear model via penalized maximum likelihood. It is able to regularize both
by LASSO and elastic net penalty, and uses lambda as the regularization pa-
rameter [5]. It is authored by Jerome Friedman, Trevor Hastie, Rob Tibshirani
and Noah Simon. In matlab, the function we used, looked like this:
[B, STATS] = lasso(X,Y,’CV’,10).
The first input, X, is the matrix of all the gene expression from the 84 differ-
ent women. This matrix was transposed after it was loaded into Matlab in order
to get the BMD with their corresponding genes in rows instead of columns. This
was done in order to make LASSO work correctly. The next input, Y, is the
Bone Mineral Density-value. This input was also transposed in order to get all
the women in one column. It is important to make sure that the values of the
X -matrix, corresponds correctly to the Y -values. CV, says us that we will use
cross validation in order to compute the MSE. 10, tells us that we will split the
84 women in 10 different folds for the cross validation process. B and STATS
are the outcomes . STATS contains information about the model fit, and this is
where we find the value of λ and the indexes connected to lambda, used to find
the numbers in B that not equals zero. B is a vector with the fitted coefficients.
For more details see the matlab command help lasso.
9.1 GLMNET - example
In order to see how well LASSO works and how accurate it is on selecting the
right genes, we ran a simulated test on 1000 genes. It was done by picking
the 10 first genes from the probeset. The chosen genes were given a randomly
selected bp between 0.1 and 0.2 or 10 and 20 and was used to make simulated
values for y for each of the 84 women. How this is done, will be explained below.
In order to progress further, we had to standardize the values of the different
x. We standardized the covariates x to have zero mean and variance 1, so their
coefficients, beta, are on the same scale. In that way they can be penalized all
in the same way with the same lambda.
When this was done, we generated the simulated values of y, following the
model:
Yi =
10∑
p=1
bpXip + (Ni)(0, σ
2), where i is each woman, i = 1, ..., 84.
The first part of the model before the +-sign, is the normal way of summation
to make a value Y. The second part is added in order to make the model show
more variability. It is made up from a NORMAL random number distributed
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Figure 6: The figure shows us the results with small and large values of the
betas for the 10 first genes, and the influence of sigma the difficulty of choosing
the right genes.
with mean 0 and a σ2 = 0, 1
The simulated Yi, was used to test more genes from the probeset. We picked
the first 1000 genes which also contain the 10 genes which are really relevant
for y, and ran LASSO on this selection. The 1000 genes were also standardized
like we did on the first 10 genes. The result from LASSO showed how well the
model worked in order to pick the 10 genes we used to simulate the Y ′s. A
good match shows us that LASSO is accurate and can be used in order to select
which genes that influence BMD most.
The results are showed in Figure 6, where we change δ too.
As seen with small values of b, LASSO is able to find some of the 10 correct
genes as long as the noise from sigma is not too big. With large b, LASSO has no
problems finding the correct genes. We also see that the amount of false positive
genes decreases with less noise from sigma. The conclusion of these findings,
is that LASSO is able to choose the correct genes, as long as the beta for the
gene have a big enough value. We do not know if this is the case for our BMD
data, but have to assume so. If this is the case, we will find important genes.
If not we might end up with false positives. A validation based on literature
comparison will help us further.
10 Bone Data
The women from this study were selected from 301 non-related postmenopausal
ethnic Norwegian women, aged 50-86 years. They were recruited at the out-
patient clinic at Lovisenberg Deacon Hospital in Oslo. 173 were rejected be-
cause of medical reasons (underlying diseases other than OP, receiving medical
treatment that might affected bone remodelling or secondary causes to OP). 23
women later decided to withdraw from the project. All the women had a normal
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endocrine, biochemical, clinical and nutritional status, but differed according to
the BMD of the spine, femoral neck and hip. The mean age was 64.6 years and
the mean BMD was 24.2 kg/cm2. Mean levels of vitamin K, Ca2+, parathy-
roid hormone (PTH), phosphate 25(OH)vitD, carboxy-terminal telopeptide of
type 1 collagen (1CTP), bone specific alkaline phosphatase and calcitonin were
all within normal ranges. All groups included women that had been oestrogen
users (oral contraceptives or perimenopausal treatment), but all of them had
not used estrogen within 2 years prior to the sudy, except one. The remain-
ing 100 women had trans-iliacal bone biopsies taken. 84 of these biopsies were
selected for gene expression analysis. Two of the healthy women were subject
for bilatetral os ileum biopsies, in order to look after molecular heterogenity.
There was also taken bone biopsies from the spine (L1-L4). The same women
were also measured by Total hip Dual-Energy X-ray Absorptiometry (DEXA)
in order to measure BMD [11] [16].
10.1 Ethics, life style factors, BMD measurement
The Norwegian Regional Ethic Commitee gave validation and recommendations
prior to the study, and all samples and procedures were according to the Law of
Biobanking in Norway. All women who volunteered were given a full clinical ex-
amination, as well as laboratory analyses and DEXA of the spine (L1-L4), total
hip, femoral neck and trochanter [11]. After completing questionares about sev-
eral factors, one of them life style factors, the women were divided into cohorts.
Since the women were Oslo-based, the cohort was seen upon as a representative
for this group of women between the age of 50-86 years. All the participants, fol-
lowed normal norwegian nutritional traditions: Dark bread (4 to 6 pieces/day),
regular intake of milk as adults, daily intake of food containing meat or fish to-
gether with mostly potatoes, cod liver oil as vitamin D supplement in childhood,
minerals (calcium and magnesium) and moderate intake of alcohol (at most, 1
to 4 glasses of wine or beer per week and seldom strong liquor). 80% took
multivitamin (including vitamin A and D). The subjects were selected to three
different groups according to their activity level: Group 1: active participation
in physical exercise at least three times per week in addition to entertaining
an active walking/hiking habit daily on the weekends. Group 2: active walk-
ing/hiking habits on the weekends but without organized exercise. Group 3:
active walking related to housework, shopping, and occasionally on the week-
ends. From the questionaries, it was calculated that the daily intake of vitamin
D and calcium was 655±80(mean±SD)IU/day and 0, 73±0, 45(mean±SD),
respectively. The bone measurements of the L1-L4 varied with 3%. The in-
strumental variety of successive measurements reported on the Lunar Prodigy
Instrument was 1, 66% for L1-L4, and 1, 14% for total hip. The manufacturer
provided the database for determination of the Z-score [11] [16].
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10.2 Bone biopsies
The bone biopsies were taken from the same place on the os ileum (2,0 cm from
crista iliaca and 2 cm from spina iliaca), usually from the right side if the pa-
tient had not done hip surgery there. In the operated cases the biopsies were
taken from the left side. On two of the patients, bilateral biopsies were taken.
These 2 samples showed 98% similarity. The biopsies had a cylindrical diameter
of 0,8 cm, and a average length of about 1,5 cm. Before they were freezed in
nitrogen, connective tissue and muscle were removed. The range of weight of
the biopsies was 0,35 - 0,70 g with a mean of 0,5 g. All biopsies were taken on
fasting individuals in the morning. [11] [16]
10.3 Microarray analysis
With the use of GeneChip R©Expression 3’ Amplification One-Cycle Target La-
beling Kit (Affymetrix), double stranded cDNA and biotin-labeled cRNA probes
were made. According to the manufacturers instruction, the cRNA was hy-
bridized to HG-U133 plus 2.0 chips (Affymetrix), and was then washed and
stained on the GeneChip Fluidics Station 450 (Affymetrix) before they were
scanned on the Affymetrix Gene Chip Scanner 3000. The quality of the RNA
and probes were controlled by an Affymetrix-based test, measuring the ratio
between 5’ and 3’ mRNAs for β-actin and GAPDH, and was found to have an
agreeable level. The datas found have been submitted to the European Bioin-
formatics Institute (EMBL-EBI) ArrayExpress repository, ID: E-MEXP-1618
[16].
10.4 Microarray data pre-processing and evaluation
Probe sets containing more than 43 absent calls were eliminated (according to
the Affymetrix MAS 5.0 software). This reduced the amount of informative
probes from 54 675 to 22 185. To normalize the data, the PLIER (Probe Loga-
rithmic Intensity Error)-algorithm was used in order to calculate relative signal
values for each probe set. To show the number of present and absent calls for
each probe set, there was created an Absolute Call dataset, using the MAS5 al-
gorithm in Array Assist to discover and filter out low signal values. Correlation
(Pearson) was computed between expression of each gene, and the BMD across
84 women using log transformed signal values. For each gene, zero correlation
was tested against the two tailed hypothesis[16]. All this work were done by
Sjur Reppe and his research group. The numbers we have been working with
in this project, is a result of their preparing.
17
11 Results
11.1 Genes found by LASSO
We ran the LASSO function independently 100 times and ended up with unique
55 genes. These can be seen in Figure 7. As seen from the table, 34 of the
genes are repeated more than 80 times and 22 genes were found in each of the
100 runs. There are some genes just repeated a single time, but we have chosen
to still take them with us in the further evaluation.
The reason we ran LASSO 100 times, is because the genes vary for each run.
It happens since we run the cross validation 10-fold. The 84 women are divided
at random into 10 subsets of about 8 women each. Then lasso is run using 9 of
these subsets and the last subset is used as the validation set. This is repeated
10 times. Every time we rerun lasso it makes a new random division into 10
subsets. This means that in each run, the CV construction is different and leads
to results with some variation
11.2 Correlation
The genes found by LASSO were then correlated against the genes found in
earlier research made on the gene material we had. We picked all the genes that
were upregulated from the The Molecular disease map-study [11], since these
are the genes of most importance on the gene expression. (The genes that are
downregulated, are so because they are controlled to do this by the upregulated
genes. This means that the genes really making an impact on the BMD will
be the upregulated ones). From the paper Eight genes are highly associated
with BMD-study [16] both negative and positive correlated genes were picked.
There were about 30 genes found in other papers [12] [7] [13] [20]. Among the
literature genes, 10 were not found in the probeset we used, even though we
looked after aliases. They can be seen in Figure 8.
We ended up with about 200 genes from the literature present in our probe-
set and correlated them against the 55 genes found by LASSO. A part of the
correlation-table can be seen in Figure 11. The whole table can be seen in
supplemental table 1.
In Figure 10 every gene in the literature is correlated with the 55 LASSO
genes. In Figure 11 each row is one of the 55 LASSO genes, correlated with
the 200 literature genes. We see a clear tendency of confirmation of our LASSO
findings.
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Figure 7: The table shows the 55 unique genes found after running LASSO 100
times. The numbers on the left shows how many times they were selected.
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Figure 8: The table shows the genes previously known to relate to BMD not
found in our probeset. The ones in bold are from [11], The normal ones are
from [16] and the ones in italic are from the other articles [12] [7] [13] [20].
12 Discussion
12.1 Findings
Our findings are reported in Figure 12. As seen from the figure, many of
the genes found by LASSO have high correlation to the literature-genes. Often
we see that the LASSO genes also correlate with many of the literature genes.
Starting from left in the figure, the first column on the left are the LASSO genes
with highest correlations with the literature genes above 0,5. The second column
shows the LASSO genes with most correlations with the literature genes above
0,35. The third column shows the LASSO genes with the highest correlation
against single literature genes and the last column shows how many times the
LASSO genes were selected in all of the 100 LASSO runs. This may indicate
that their impact on BMD is quite strong. What is possibly interesting is that
AFFX-M27830 M at appeared only once in all of the 100 LASSO-runs, but is
present among the literature genes. You can also see that ATP5SL, TNXA
/// TNXB, SOST, PBXIP1, SNCA, GTF2F2, DPP8, C4orf31, TFDP2 and
MCF2L all are among the top 10-11 genes in every column in Figure 12, which
means they both have a high correlation to single literature genes, as well as they
show a high correlation to many of the literature genes. They were also selected
many times in all of the 100 LASSO runs. This may be an indicator that these
LASSO genes have an important function in bone homoeostasis. The rest of the
genes found by LASSO may also have an important role in bone homoeostasis,
except for the genes SMARCA4, 239845 at, LOC100287628, PBX2, which did
not show any correlation to any of the genes found in earlier research. These
might be false positives or new discoveries, but possibly they are new findings.
Validation would be necessary.
12.2 Validity
By using LASSO, we use a statistical method in order to find the genes. In
order to see the validity of the LASSO-findings, we made a simulated example
as seen earlier in the paper. The conclusion from that simulation (results can
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Figure 9: Correlation between the 10 most correlated genes found in the lit-
erature and the genes found by LASSO, with the most correlation on the top.
Correlation >0,35 is marked with red and correlation >0,5 is marked yellow.
Genes found in both the literature and by LASSO have correlation = 1 and is
marked green. The literature genes in bold are from [11], the normal ones are
from [16] and the ones in italic are from the other articles [12] [7] [13] [20].
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Figure 10: Each row shows one of the literature genes and which LASSO-genes
they correlate with. The colours show grade of correlation. Correlation >0,35
= red, correlation >0,5 = yellow and correlation = 1 = green.
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Figure 11: Each row shows one of the LASSO-genes and which literature-genes
they correlate with. The colours show grade of correlation. Correlation >0,35
= red, correlation >0,5 = yellow and correlation = 1 = green.
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Figure 12: Starting from left in the figure, the first column on the left are the
LASSO genes with highest correlations above 0,5 with the literature genes. The
second column shows the LASSO genes with most correlations above 0,35 with
the literature genes. The third column shows the LASSO genes with the highest
correlation against single literature genes and the last column shows how many
times the LASSO genes were selected in all of the 100 LASSO runs.
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be seen in figure 6), was that as long as the Beta-values were big enough, we
should be able to find all the correct genes, but we are also in danger of finding
false positives when the noise is strong. Beta values say how much the actually
important genes affect BMD, in absolute value. We do not know this, but on
the other hand small effects (which we would not find) might be important.
We find that 51 of the LASSO genes correlates more than 0,35 with the
expression of genes found in the literature. 21 of the genes correlates more than
0,5. This indicates that our 51 genes are true findings. We also checked if any
of the LASSO had aliases that were the same as the literature-genes, which it
was not. The conclusions of our findings is that most of the LASSO-findings
are reliable, as it is correlated to genes already known being associated to bone
mechanisms.
12.3 Limitations
The genes used in this experiment, are from biopsies taken from the hip. The
Z-values we used for BMD, were only adjusted for age. We might have got some
bias due to confounding factors such as BMI which we have not investigated this
time. There might be other influencing factors that make some bias that we do
not know about. The cohort was well designed, taking into account influencing
factors such as nutrition, activity and daily intake of vitamin D and Calcium
[11] [16]. On the other hand, the Z-values are not adjusted for blood values of
PTH, Calcium or 25(OH)vitD. Since the women were Oslo-based, the cohort
may be seen as representative for this group of women between the age of 50-86
years. We can not generalize the findings much further.
12.4 Functional assessment
The biological function of a selection of the 20 highest ranked genes from Figure
12 are shown in Figure 13. The genes shown are those in which we found most
information about in the literature.
Of the function and pathways seen, SOST seems to be the one of most
interest. It is a gene known for being a negative regulator of bone-growth. It is
also involved in the Wnt-pathway, which is central in bone turnover. Another
interesting gene is MCF2L, which seems to have some interaction with the gene
RHOA.
12.5 Conclusion
The LASSO is a method for finding genes involved in biological processes. It
seems to be a valid method for selecting the right genes. We found 51 genes
highly associated with BMD and mostly correlated to genes already found in
the literature for having an impact on BMD. Among these, we found one gene,
SOST , that for sure is known to have impact on BMD. Another gene, MCF2L,
seems to have some cooperation with RHOA. 4 genes found by LASSO were
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Figure 13: Functions and pathways for some of the top 10-20 ranked genes from
Figure 12 in which we found most information about [8] [15]
.
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previously known as regulating genes. Our study strengthens the probability
that they really have an impact on BMD. There were 4 new genes, not correlated
to any gene known previously to play a role in bone mechanisms, and these might
be new discoveries or false positives. To find this out, we need to do further
investigations. The rest of the LASSO genes seems to be highly associated to
BMD.
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